miR-181b Nucleic Acid Therapy for Vascular Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vascular inflammatory diseases, such as atherosclerosis, often rely on therapies that target NF-PB signaling but come with negative side effects, and there is a need for more effective methods to inhibit NF-PB-mediated endothelial cell activation and leukocyte adhesion.
Innovation Solution
Administration of a nucleic acid containing the sequence of miR-181b, which inhibits TNF-α-induced NF-PB-mediated up-regulation of adhesion molecules, thereby reducing leukocyte adhesion and expression of VCAM-1, E-selectin, and ICAM-1 in endothelial cells, thereby addressing NF-PB signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies targeting NF-PB signaling are used to treat vascular inflammatory diseases, then the effectiveness in inhibiting endothelial cell activation and leukocyte adhesion is improved, but negative side effects increase
Solution Approach 1:
The patent changes the therapeutic parameter from direct NF-PB signaling inhibitors to miR-181b nucleic acid molecules, which indirectly regulate NF-PB-mediated pathways through post-transcriptional control of target genes including VCAM-1, E-selectin, and ICAM-1. This parameter change maintains therapeutic effectiveness while reducing harmful side effects by targeting specific molecular pathways rather than broad NF-PB signaling.
Solution Approach 2:
The patent introduces miR-181b as an intermediary molecule that mediates the inhibition of adhesion molecules and NF-PB signaling pathways. Instead of directly targeting NF-PB signaling components, the miR-181b nucleic acid acts as an intermediate regulator that reduces VCAM-1, E-selectin, and ICAM-1 expression, thereby treating vascular inflammatory diseases with improved safety profile.
2Reliability
If miR-181b nucleic acid is administered to inhibit NF-PB-mediated adhesion molecule expression, then leukocyte adhesion is reduced, but the complexity of the treatment increases
Solution Approach 1:
The patent employs miR-181b nucleic acid molecules that possess multi-functional capabilities: they can inhibit multiple adhesion molecules (VCAM-1, E-selectin, ICAM-1) simultaneously, target multiple pathways downstream of NF-PB signaling, and be delivered through various administration routes. This universality reduces treatment complexity by achieving multiple therapeutic effects with a single therapeutic agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly decreases leukocyte adhesion and expression of inflammatory molecules, effectively treating or delaying the onset of atherosclerosis and other vascular inflammatory diseases by specifically targeting NF-PB signaling pathways.
Implementation Method 1
overexpression of miR-181b in endothelial cells inhibited TNF-α-induced NF-PB-mediated up-regulation of vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and intracellular adhesion molecule-1 (ICAM-1) expression
Data Source
Figure 1A~1C
Figure 1D
Figure 1E
AI summary
Provided are methods of treating or delaying the onset of a vascular inflammatory disease (e.g., acute lung injury) in a subject including administering to the subject a therapeutically effective amount of a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1). Also provided are methods of decreasing nuclear factor-Pβ (NF-Pβ) signaling in an endothelial cell including administering to the subject a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1).